Last ¥1,410 JPY
Change Today -4.00 / -0.28%
Volume 792.0K
4151 On Other Exchanges
As of 2:00 AM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/14 - ¥1,510
52 Week Low
09/13/13 - ¥980.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,152 Employees
Last Reported Date: 03/14/14
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan

Kyowa Hakko Kirin Co., Ltd. announced the initiation of a phase 2b clinical study evaluating KHK7580 for secondary hyperparathyroidism patients receiving hemodialysis in Japan. This randomized, placebo-controlled, double-blind, parallel-group, multi-center study is designed to evaluate efficacy and safety in cohorts comprising KHK7580, its placebo and cinacalcet and initial dose of KHK7580 for secondary hyperparathyroidism patients receiving hemodialysis.

Kyowa Hakko Kirin Co., Ltd. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year Ending December 31, 2014

Kyowa Hakko Kirin Co., Ltd. reported consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported net sales of JPY 161,899 million against JPY 169,707 million a year ago. Operating income was JPY 18,411 million against JPY 27,176 million a year ago. Ordinary income was JPY 16,865 million against JPY 26,523 million a year ago. Income before income taxes and minority interests was JPY 16,752 million against JPY 30,856 million a year ago. Net income was JPY 9,185 million or JPY 16.77 per diluted share against JPY 17,678 million or JPY 32.27 per diluted share a year ago. Net cash used in operating activities was JPY 548 million against cash flow from operating activities of JPY 20,675 million a year ago. Purchase of property, plant and equipment was JPY 16,306 million against JPY 10,794 million a year ago. Purchase of intangible assets was JPY 1,966 million against JPY 12,755 million a year ago. Capital expenditure was JPY 12.1 billion against JPY 9.6 billion a year ago. For the second quarter, the company reported net sales of JPY 75.8 billion against JPY 83.0 billion a year ago. Operating income was JPY 5.9 billion against JPY 12.7 billion a year ago. Ordinary income was JPY 4.8 billion against JPY 11.6 billion a year ago. Income before income taxes and minority interests was JPY 4.3 billion against JPY 12.2 billion a year ago. Net income was JPY 2.8 billion against JPY 7.1 billion a year ago. EPS prior to amortization of goodwill were JPY 9.44 against JPY 17.36 a year ago. For the fiscal year ending December 31, 2014, the company expects net sales of JPY 337,000 million, operating income of JPY 45,000 million, ordinary income of JPY 37,000 million, net income of JPY 20,000 million or JPY 36.54 per basic share, income before income taxes and minority interests of JPY 35.5 billion and capital expenditure of JPY 30.0 billion.

AstraZeneca and Kyowa Hakko Kirin Partner on Immuno-Oncology Clinical Study

AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours. The study will evaluate AstraZeneca's anti-PD-L1 antibody, MEDI4736, in combination with Kyowa Hakko Kirin's anti-CCR4 antibody, mogamulizumab, and AstraZeneca's anti-CTLA-4 antibody tremelimumab, in combination with mogamulizumab. MEDI4736, tremelimumab, and mogamulizumab are part of a new class of cancer treatments known as immunotherapies, which use the body's own immune system to help fight cancer. MEDI4736 and tremelimumab block the signals that help tumours avoid detection by the immune system, while mogamulizumab suppresses some of the immune cells that shield the tumour from the immune system. Under the terms of the agreement, AstraZeneca and Kyowa Hakko Kirin will co-fund the study, which will be conducted by Kyowa Hakko Kirin. The Phase I part of the study is expected to establish a recommended dose regimen and Phase Ib will assess the safety and efficacy of the two combinations. Results from these studies will determine the future clinical development of the combinations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥1,410.00 JPY -4.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $63.70 USD +0.12
Nabaltec AG €10.40 EUR -0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation 4151 Industry Range
Price/Earnings 34.7x
Price/Sales 2.3x
Price/Book 1.3x
Price/Cash Flow 19.2x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at